DEX-G2 Biomarker Test for Early Detection of Gastric Cancer

Coming Soon to U.S. Clinical Settings

A New Era in Blood-Based Gastric Cancer Detection

DEX-G2 is a minimally invasive, PCR-based blood test designed to support early detection of gastric cancer. The test was developed through decades of research led by Ajay Goel, Ph.D., AGAF, a globally recognized expert in gastrointestinal cancer biomarkers who now serves as senior investigator at the City of Hope Comprehensive Cancer Center. DEX-G2 analyzes a proprietary combination of cell-free and exosomal miRNA biomarkers associated with gastric tumorigenesis—offering physicians a powerful new tool to enhance early clinical decision-making in high-risk patients. 

Test Performance

0%

Sensitivity for Early-Stage Gastric Cancer

0%

Specificity for Early-Stage Gastric Cancer

AUC

0.00

Training

0.00

Validation

Validation in the DESTINEX multicancer clinical trial of nearly 1,000 patient samples, published in JAMA Surgery

Supports clinical decision-making in primary care and specialty practices

DEX-G2 may aid in risk stratification and early detection in the following clinical scenarios:

Potential Clinical Use Cases

  • At-risk patients over 40 with persistent upper GI symptoms and/or family history

  • Adjunctive tool to help prioritize referrals for endoscopy or imaging

  • Surveillance in previously treated patients with early-stage gastric cancer

  • Populations with elevated gastric cancer risk, including Hispanic, Asian, and Eastern European ancestry or regions such as South Texas

  • Patients with Helicobacter pylori infection or pre-neoplastic gastric changes

When the Test is Positive—A Sample Diagnostic Pathway

1

DEX-G2 Positive Result

2

Upper endoscopy with biopsy

3

Histopathologic confirmation

4

Multidisciplinary treatment planning* (surgery radiation, or systemic therapy)

*Note: DEX-G2 is designed to complement—not replace—standard diagnostic and surveillance protocols. Clinical decisions remain at the discretion of the treating provider.

Ordering and Logistics for Clinicians

When available, licensed U.S. healthcare providers can order the DEX-G2 test via a secure online portal on this clinician page.

  • Test type – PCR-based molecular assay (LDT – Laboratory Developed Test)

  • Ordering – Available to licensed U.S. healthcare providers via secure online portal

  • Processing – Performed by CLIA-certified, CAP-accredited partner laboratories

  • Turnaround time – 72 hours from receipt of sample

  • Billing – Initially private pay; CPT application to follow

  • Support – Full-service customer support team with access to Chief Medical Officer for clinical questions

Stay Informed

For updates or to request notification when the test becomes available, please sign up below for email alerts.